'Treatment Holiday' in Prostate Cancer With Tailored Dosing

Using early-response biomarkers in patients treated with lutetium-177 PSMA-617 can help personalize dosing intervals and potentially improve outcomes.
Medscape Medical News

source https://www.medscape.com/viewarticle/994753?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?